- Akari Therapeutics ( NASDAQ: AKTX ) on Thursday said a patient had completed a course of treatment with its inhibitor nomacopan in its phase 3 part A trial in kids with hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).
- HSCT-TMA is a complication that can happen following a stem cell transplant procedure which can lead to tissue hypoxia, blood clots and progressive organ damage and death.
- AKTX said one of the three patients with severe HSCT-TMA in the trial completed more than 60 days of treatment with nomacopan and was subsequently discharged from the hospital.
- Another patient died due to multi-organ failure that was unrelated to the treatment with nomacopan.
- Dosing has started in the third patient.
- Nomacopan had previously been granted orphan drug and fast track designations by the U.S. FDA for pediatric HSCT-TMA.
- U.S.-listed shares of AKTX gained 12.6% to $1.07 in early trading.
For further details see:
Patient completes course with Akari's stem cell transplant related complication treatment